enalaprilat Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 1006 76420-72-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • enalaprilat
  • enalapril acid
  • enalaprilate
  • enalaprilic acid
  • enalaprilat hydrate
  • enalaprilat dihydrate
The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.
  • Molecular weight: 348.40
  • Formula: C18H24N2O5
  • CLOGP: 0.75
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 106.94
  • ALOGS: -2.60
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.91 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.38 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.62 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 39 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 9, 1988 FDA BIOVAIL LABS INTL

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:35674 antihypertensive
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Congestive heart failure indication 42343007 DOID:6000
Asymptomatic left ventricular systolic dysfunction indication 698592004
Angioedema contraindication 41291007 DOID:1558
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Idiopathic angioedema contraindication 402382008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.12 acidic
pKa2 3.14 acidic
pKa3 8.3 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 7.50 IUPHAR IUPHAR
Angiotensin-converting enzyme Enzyme Ki 8.85 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 9.02 CHEMBL
Angiotensin-converting enzyme 2 Enzyme Ki 9.30 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 7.94 CHEMBL

External reference:

IDSource
4019497 VUID
N0000147617 NUI
D03769 KEGG_DRUG
4019497 VANDF
C0014027 UMLSCUI
CHEBI:4786 CHEBI
EAL PDB_CHEM_ID
CHEMBL577 ChEMBL_ID
CHEMBL3989406 ChEMBL_ID
DB09477 DRUGBANK_ID
D015773 MESH_DESCRIPTOR_UI
5462501 PUBCHEM_CID
6332 IUPHAR_LIGAND_ID
84680-54-6 SECONDARY_CAS_RN
GV0O7ES0R3 UNII
3829 RXNORM
37933 MMSL
4657 MMSL
004369 NDDF
007388 NDDF
414092003 SNOMEDCT_US
48052001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Enalaprilat HUMAN PRESCRIPTION DRUG LABEL 1 0143-9786 INJECTION 2.50 mg INTRAVENOUS ANDA 23 sections
Enalaprilat HUMAN PRESCRIPTION DRUG LABEL 1 0143-9787 INJECTION 1.25 mg INTRAVENOUS ANDA 23 sections
ENALAPRILAT HUMAN PRESCRIPTION DRUG LABEL 1 51662-1477 INJECTION 1.25 mg INTRAVENOUS ANDA 13 sections